Article
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Japanese journal of clinical oncology - 1 Aug 2021
Sakai Hiroshi, Morise Masahiro, Kato Terufumi, Matsumoto Shingo, Sakamoto Tomohiro, Kumagai Toru, Tokito Takaaki, Atagi Shinji, Kozuki Toshiyuki, Tanaka Hiroshi, Chikamori Kenichi, Shinagawa Naofumi, Takeoka Hiroaki, Bruns Rolf, Straub Josef, Schumacher Karl Maria, Paik Paul K
Abstract excerpt
BACKGROUND: MET exon 14 skipping is an oncogenic driver occurring in 3-4% of non-small cell lung cancer (NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipping NSCLC. Here, we present data from Japanese patients in the Phase II VISION study, evaluating the efficacy and safety of tepotinib. METHODS: In the open-label, single-arm, Phase II VISION study, patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.